KDR and breast cancer: As such, our preclinical studies might offer a new biomarker-guided combination treatment option that includes a PARPi (e.g., talazoparib) and a VEGFR inhibitor (e.g., axitinib) to specifically target PARPi-resistant breast cancers that express FLT1.